To this end, we conducted several analyses using the Swedish Apolipoprotein-Related Mortality Risk (AMORIS) Cohort, including a sample size of over half a million and a follow-up of up to 35 years, with the aim of evaluating the association between the baseline level of blood inflammatory biomarkers that are commonly measured clinically (e.g., CRP, haptoglobin, albumin, platelets, sedimentation rate, and counts as well as frequencies of immune cells) and the subsequent risk of HNC, focusing on analyzing HNC by histopathology type and cancer site. This evidence concerns the gene CRP and cancer.